orgovyx
accord healthcare s.l.u. - relugolix - prostatic neoplasms - endocrine therapy - orgovyx is indicated for the treatment of adult patients with advanced hormone-sensitive prostate cancer.
orserdu
stemline therapeutics b.v. - elacestrant - breast neoplasms - endocrine therapy - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.
degarelix accord
accord healthcare s.l.u. - degarelix acetate - prostatic neoplasms - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer.for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
accofil (filgrastim) 30 mu0.5 ml solution for injectioninfusion in prefilled syringe
accord healthcare sdn.bhd. - filgrastim -
accofil (filgrastim) 48 mu0.5 ml solution for injectioninfusion in prefilled syringe
accord healthcare sdn.bhd. - filgrastim -
afinitor
novartis pharmaceuticals australia pty ltd - everolimus -
neupogen 30 mu vials
amgen europe b.v. - filgrastim - solution for injection - filgrastim 30 mu/ml - filgrastim - filgrastim - neupogen is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia.the safety and efficacy of neupogen are similar in adults and children receiving cytotoxic chemotherapy.neupogen is indicated for the mobilisation of peripheral blood progenitor cells (pbpcs).in patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (anc) of ≤ 0.5 × 109/l, and a history of severe or recurrent infections, long term administration of neupogen is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.neupogen is indicated for the treatment of persistent neutropenia (anc less than or equal to 1.0 × 109/l) in patients with advanced hiv infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.
neupogen 48 mu pre-filled syringe
amgen europe b.v. - filgrastim - solution for injection - filgrastim 48 mu / 0.5 ml - filgrastim - filgrastim - neupogen is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia.the safety and efficacy of neupogen are similar in adults and children receiving cytotoxic chemotherapy.neupogen is indicated for the mobilisation of peripheral blood progenitor cells (pbpcs).in patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (anc) of ≤ 0.5 × 109/l, and a history of severe or recurrent infections, long term administration of neupogen is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.neupogen is indicated for the treatment of persistent neutropenia (anc less than or equal to 1.0 × 109/l) in patients with advanced hiv infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.
neupogen 30 mu pre-filled syringe
amgen europe b.v. - filgrastim - solution for injection - filgrastim 30 mu / 0.5 ml - filgrastim - filgrastim - neupogen is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia.the safety and efficacy of neupogen are similar in adults and children receiving cytotoxic chemotherapy.neupogen is indicated for the mobilisation of peripheral blood progenitor cells (pbpcs).in patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (anc) of ≤ 0.5 × 109/l, and a history of severe or recurrent infections, long term administration of neupogen is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.neupogen is indicated for the treatment of persistent neutropenia (anc less than or equal to 1.0 × 109/l) in patients with advanced hiv infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.
folotyn® solution for infusion 20mgml
mundipharma pharmaceuticals pte. ltd. - pralatrexate - infusion, solution - 20mg/ml - pralatrexate 20mg/ml